Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials

Clin Exp Rheumatol. Mar-Apr 2010;28(2 Suppl 58):S55-62. Epub 2010 Jun 24.

Abstract

Pulmonary disease is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). Recent well-designed trials in SSc-associated interstitial lung disease (SSc-ILD) have provided important insights regarding outcome measures and trial design. Recent investigations into the pathogenesis of SSc-ILD have led to a renewed interest in assessing targeted therapies in SSc-ILD. With this in mind, we propose recommendations for the design of future SSc-ILD studies in this review.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Endpoint Determination
  • Humans
  • Lung Diseases, Interstitial / drug therapy
  • Lung Diseases, Interstitial / etiology*
  • Lung Diseases, Interstitial / physiopathology
  • Multicenter Studies as Topic
  • Randomized Controlled Trials as Topic / methods*
  • Research Design
  • Scleroderma, Systemic / complications*
  • Scleroderma, Systemic / drug therapy
  • Scleroderma, Systemic / physiopathology
  • Severity of Illness Index
  • Treatment Outcome
  • Vital Capacity